Daewoong pancreatitis drug tested as Covid-19 treatmentDaewoong Pharmaceutical’s pancreatitis drug was approved to undergo Phase 2 clinical trials as a coronavirus treatment in Mexico, the Korean company said Monday.
Daewoong’s Foistar tablets, made of camostat mesilate, will be tested on 180 coronavirus patients with light or moderate symptoms, for 40 days. The trial will be conducted by researchers at the Salvador Zubirán National Institute of Health Sciences and Nutrition.
Developed and currently sold in the market as a treatment for pancreatitis and reflux esophagitis, Foistar tablets also received approval from Korea’s Ministry of Food and Drug Safety in July for Phase 2 clinical trials. The Phase 1 tests, mainly aimed to verify safety, were waived considering the product is already in use.
Daewoong plans to further expand the number of countries for testing Foistar as a Covid-19 treatment. Its DWRX2003, which is niclosamide, was approved for Phase 1 clinical trials in India and the Philippines.
BY SONG KYOUNG-SON [firstname.lastname@example.org]
with the Korea JoongAng Daily
To write comments, please log in to one of the accounts.
Standards Board Policy (0/250자)